Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah cannon research institute

Journal of Clinical Oncology

Volumn 31, Issue 2, 2013, Pages 217-223

  Hainsworth, John D ^a,b   Rubin, Mark S ^c   Spigel, David R ^a,b   Boccia, Ralph V ^d   Raby, Samuel ^a   Quinn, Raven ^a   Greco, F Anthony ^a,b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b Tennessee Oncology   (United States)

^c Florida Cancer Specialists   (United States)

^d Center for Cancer and Blood Disorders   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; OXALIPLATIN; PACLITAXEL; RECOMBINANT INTERFERON; SUNITINIB;

ADULT; AGED; ANDROGEN ABLATION THERAPY; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BILE DUCT CARCINOMA; BREAST CARCINOMA; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER PATIENT; CANCER SURVIVAL; COLORECTAL CARCINOMA; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; KIDNEY CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVARY CARCINOMA; PANCREAS CARCINOMA; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL TIME; TUMOR BIOPSY; URINARY TRACT CARCINOMA; UROTHELIUM CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84872567958     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.3755     Document Type: Article

References (27)

1. Greco FA, Erland JB, Morrissey LH, et al: Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin. Ann Oncol 11:211-215, 2000 (Pubitemid 30148737)
2. Briasoulis E, Kalofonos H, Bafaloukos D, et al: Carboplatin plus paclitaxel in unknown primary carcinoma: A phase II Hellenic Cooperative Oncology Group Study. J Clin Oncol 18:3101-3107, 2000
3. Culine S, Lortholary A, Voigt JJ, et al: Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: Results of a randomized phase II study-Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01). J Clin Oncol 21:3479-3482, 2003 (Pubitemid 46594080)
4. Greco FA, Pavlidis N: Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Semin Oncol 36:65-74, 2009
5. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342, 2004 (Pubitemid 38702844)
6. Escudier B, Bellmunt J, Négrier S, et al: Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analyses of overall survival. J Clin Oncol 28:2144-2150, 2010
7. Erlander MG, Ma XJ, Kesty NC, et al: Performance and clinical evaluation of the 92-gene real time PCR assay for tumor classification. J Mol Diagn 13:493-503, 2011
8. Pillai R, Deeter R, Rigl CT, et al: Validation and reproducibility of a microarray-based gene expression test for tumor identification in formalin-fixed, paraffin-embedded specimens. J Mol Diagn 13:48-56, 2011
9. Varadhachary GR, Edmonston TB, Karanth S, et al: Prospective gene signature study using microRNA to predict the tissue of origin (ToO) in patients with cancer of unknown primary site (CUP). J Clin Oncol 28:155, 2010 (suppl; abstr 4151)
10. Varadhachary GR, Talantov D, Raber MN, et al: Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. J Clin Oncol 26:4442-4448, 2008
11. Hainsworth JD, Pillai R, Henner WD, et al: Molecular tumor profiling in the diagnosis of patients with carcinoma of unknown primary site: Retrospective evaluation of gene microarray assay. J Mol Biomark Diagn 2:106-111, 2011
12. Greco FA, Spigel DR, Yardley DA, et al: Molecular profiling in unknown primary cancer: Accuracy of tissue of origin prediction. Oncologist 15: 500-506, 2010
13. Greco FA, Hainsworth JD: Cancer of unknown primary site, in DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology (ed 9). Philadelphia, PA, J.B. Lippincott, 2011, pp 2033-2051
14. Pavlidis N, Briasoulis E, Pentheroudakis G: Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21:v228-v231, 2010 (suppl 5)
15. Bugat R, Bataillard A, Lesimple T, et al: Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site. Br J Cancer 89:S59-S66, 2003 (suppl 1) (Pubitemid 37076150)
16. Ma XJ, Patel R, Wang X, et al: Molecular classification of human cancers using a 92-gene real-time quantitative polymerase chain reaction assay. Arch Pathol Lab Med 130:465-473, 2006
17. Piga A, Nortilli R, Cetto GL, et al: Carboplatin, doxorubicin and etoposide in the treatment of tumors of unknown primary site. Br J Cancer 90:1898-1904, 2004 (Pubitemid 38746328)
18. Greco FA, Burris HA 3rd, Litchy S, et al: Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: A Minnie Pearl Cancer Research Network study. J Clin Oncol 20:1651-1656, 2002 (Pubitemid 34260547)
19. Greco FA, Rodriguez GI, Shaffer DW, et al: Carcinoma of unknown primary site: Sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan-A Minnie Pearl Cancer Research Institute Research Network phase II trial. Oncologist 9:644-652, 2004 (Pubitemid 39546405)
20. Hainsworth JD, Spigel DR, Clark BL, et al: Paclitaxel/carboplatin/ etoposide versus gemcitabine/ irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: A randomized, phase III Sarah Cannon Oncology Research Consortium Trial. Cancer J 16:70-75, 2010
21. Horlings HM, van Laar RK, Kerst JM, et al: Gene expression profiling to identify the histogenetic origin of metastatic adenocarcinomas of unknown primary. J Clin Oncol 26:4435-4441, 2008
22. Thompson DS, Hainsworth JD, et al: Molecular tumor profiling in cancer of unknown primary site (CUP): A complement to standard pathologic diagnoses. J Clin Oncol 29:645s, 2011 (suppl 15; abstr 10560)
23. Greco FA, Lennington WJ, Spigel DR, et al: Carcinoma of unknown primary site: Outcomes in patients with a colorectal molecular profile treated with sitespecific chemotherapy. J Cancer Ther 3:37-43, 2012
24. Hainsworth JD, Schnabel CA, Erlander MG, et al: A retrospective study of treatment outcomes in patients with carcinoma of unknown primary site and a colorectal cancer molecular profile. Clin Colorectal Cancer 11:112-1118, 2012
25. Nystrom JS, Weiner JM, Heffelfinger- Juttner J, et al: Metastatic and histologic presentations in unknown primary cancer. Semin Oncol 4:53-68, 1972
26. Pentheroudakis G, Golfinopoulos V, Pavlidis N: Switching benchmarks in cancer of unknown primary: From autopsy to microarray. Eur J Cancer 43:2026-2036, 2007 (Pubitemid 47380362)
27. Hainsworth JD, Erland JB, Kalman LA, et al: Carcinoma of unknown primary site: Treatment with 1-hour paclitaxel, carboplatin and extendedschedule etoposide. J Clin Oncol 15:2385-2393, 1997 (Pubitemid 27251142)